Literature DB >> 11106564

Reduced heparan sulfate accumulation in enterocytes contributes to protein-losing enteropathy in a congenital disorder of glycosylation.

V Westphal1, S Murch, S Kim, G Srikrishna, B Winchester, R Day, H H Freeze.   

Abstract

Intestinal biopsy in a boy with gastroenteritis-induced protein-losing enteropathy (PLE) showed loss of heparan sulfate (HS) and syndecan-1 core protein from the basolateral surface of the enterocytes, which improved after PLE subsided. Isoelectric focusing analysis of serum transferrin indicated a congenital disorder of glycosylation (CDG) and subsequent analysis showed three point mutations in the ALG6 gene encoding an alpha1,3-glucosyltransferase needed for the addition of the first glucose to the dolichol-linked oligosaccharide. The maternal mutation, C998T, causing an A333V substitution, has been shown to cause CDG-Ic, whereas the two paternal mutations, T391C (Y131H) and C924A (S308R) have not previously been reported. The mutations were tested for their ability to rescue faulty N:-linked glycosylation of carboxypeptidase Y in an ALG6-deficient Saccharomyces cerevisiae strain. Normal human ALG6 rescues glycosylation and A333V partially rescues, whereas the combined paternal mutations (Y131H and S308R) are ineffective. Underglycosylation resulting from each of these mutations is much more severe in rapidly dividing yeast. Similarly, incomplete protein glycosylation in the patient is most severe in rapidly dividing enterocytes during gastroenteritis-induced stress. Incomplete N:-linked glycosylation of an HS core protein and/or other biosynthetic enzymes may explain the selective localized loss of HS and PLE.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11106564      PMCID: PMC1885788          DOI: 10.1016/S0002-9440(10)64830-4

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  49 in total

1.  Use of heparin in the treatment of protein-losing enteropathy after fontan operation for complex congenital heart disease.

Authors:  A M Kelly; R H Feldt; D J Driscoll; G K Danielson
Journal:  Mayo Clin Proc       Date:  1998-08       Impact factor: 7.616

Review 2.  The role of the lectin calnexin in conformation independent binding to N-linked glycoproteins and quality control.

Authors:  J J Bergeron; A Zapun; W J Ou; R Hemming; F Parlati; P H Cameron; D Y Thomas
Journal:  Adv Exp Med Biol       Date:  1998       Impact factor: 2.622

3.  Phosphomannose isomerase deficiency: a carbohydrate-deficient glycoprotein syndrome with hepatic-intestinal presentation.

Authors:  J Jaeken; G Matthijs; J M Saudubray; C Dionisi-Vici; E Bertini; P de Lonlay; H Henri; H Carchon; E Schollen; E Van Schaftingen
Journal:  Am J Hum Genet       Date:  1998-06       Impact factor: 11.025

4.  Carbohydrate deficient glycoprotein (CDG) syndrome type I.

Authors:  J Jaeken; G Matthijs; R Barone; H Carchon
Journal:  J Med Genet       Date:  1997-01       Impact factor: 6.318

5.  The ALG10 locus of Saccharomyces cerevisiae encodes the alpha-1,2 glucosyltransferase of the endoplasmic reticulum: the terminal glucose of the lipid-linked oligosaccharide is required for efficient N-linked glycosylation.

Authors:  P Burda; M Aebi
Journal:  Glycobiology       Date:  1998-05       Impact factor: 4.313

6.  Isoforms and levels of transferrin, antithrombin, alpha(1)-antitrypsin and thyroxine-binding globulin in 48 patients with carbohydrate-deficient glycoprotein syndrome type I.

Authors:  H Stibler; U Holzbach; B Kristiansson
Journal:  Scand J Clin Lab Invest       Date:  1998-02       Impact factor: 1.713

7.  A novel disorder of N-glycosylation due to phosphomannose isomerase deficiency.

Authors:  T J de Koning; L Dorland; O P van Diggelen; A M Boonman; G J de Jong; W L van Noort; J De Schryver; M Duran; I E van den Berg; G J Gerwig; R Berger; B T Poll-The
Journal:  Biochem Biophys Res Commun       Date:  1998-04-07       Impact factor: 3.575

8.  A case of the carbohydrate-deficient glycoprotein syndrome type 1 (CDGS type 1) with normal phosphomannomutase activity.

Authors:  J Charlwood; P Clayton; A Johnson; G Keir; N Mian; B Winchester
Journal:  J Inherit Metab Dis       Date:  1997-11       Impact factor: 4.982

9.  Carbohydrate-deficient glycoprotein syndrome type Ib. Phosphomannose isomerase deficiency and mannose therapy.

Authors:  R Niehues; M Hasilik; G Alton; C Körner; M Schiebe-Sukumar; H G Koch; K P Zimmer; R Wu; E Harms; K Reiter; K von Figura; H H Freeze; H K Harms; T Marquardt
Journal:  J Clin Invest       Date:  1998-04-01       Impact factor: 14.808

10.  Intestinal, pancreatic and hepatic involvement in carbohydrate-deficient glycoprotein syndrome type I.

Authors:  B Kristiansson; S Borulf; N Conradi; C Erlanson-Albertsson; W Ryd; H Stibler
Journal:  J Pediatr Gastroenterol Nutr       Date:  1998-07       Impact factor: 2.839

View more
  19 in total

Review 1.  New disorders in carbohydrate metabolism: congenital disorders of glycosylation and their impact on the endocrine system.

Authors:  Bradley S Miller; Hudson H Freeze
Journal:  Rev Endocr Metab Disord       Date:  2003-03       Impact factor: 6.514

2.  ALG6-CDG in South Africa: Genotype-Phenotype Description of Five Novel Patients.

Authors:  M Dercksen; A C Crutchley; E M Honey; M M Lippert; G Matthijs; L J Mienie; H C Schuman; B C Vorster; J Jaeken
Journal:  JIMD Rep       Date:  2012-07-01

3.  Clinical utility gene card for: ALG6 defective congenital disorder of glycosylation.

Authors:  Jaak Jaeken; Dirk Lefeber; Gert Matthijs
Journal:  Eur J Hum Genet       Date:  2014-07-23       Impact factor: 4.246

4.  Reduced expression of the oligosaccharyltransferase exacerbates protein hypoglycosylation in cells lacking the fully assembled oligosaccharide donor.

Authors:  Shiteshu Shrimal; Reid Gilmore
Journal:  Glycobiology       Date:  2015-03-19       Impact factor: 4.313

Review 5.  Heparan sulfate proteoglycans.

Authors:  Stephane Sarrazin; William C Lamanna; Jeffrey D Esko
Journal:  Cold Spring Harb Perspect Biol       Date:  2011-07-01       Impact factor: 10.005

6.  Heparan sulfate and syndecan-1 are essential in maintaining murine and human intestinal epithelial barrier function.

Authors:  Lars Bode; Camilla Salvestrini; Pyong Woo Park; Jin-Ping Li; Jeffrey D Esko; Yu Yamaguchi; Simon Murch; Hudson H Freeze
Journal:  J Clin Invest       Date:  2008-01       Impact factor: 14.808

7.  ALG6-CDG: a recognizable phenotype with epilepsy, proximal muscle weakness, ataxia and behavioral and limb anomalies.

Authors:  Eva Morava; Vera Tiemes; Christian Thiel; Nathalie Seta; Pascale de Lonlay; Hans de Klerk; Margot Mulder; Estela Rubio-Gozalbo; Gepke Visser; Peter van Hasselt; Dafne D G Horovitz; Carolina Fischinger Moura de Souza; Ida V D Schwartz; Andrew Green; Mohammed Al-Owain; Graciella Uziel; Sabine Sigaudy; Brigitte Chabrol; Franc-Jan van Spronsen; Martin Steinert; Eleni Komini; Donald Wurm; Andrea Bevot; Addelkarim Ayadi; Karin Huijben; Marli Dercksen; Peter Witters; Jaak Jaeken; Gert Matthijs; Dirk J Lefeber; Ron A Wevers
Journal:  J Inherit Metab Dis       Date:  2016-06-10       Impact factor: 4.982

Review 8.  Glycosylation diseases: quo vadis?

Authors:  Harry Schachter; Hudson H Freeze
Journal:  Biochim Biophys Acta       Date:  2008-11-13

Review 9.  Clinical Approaches to the Patient with a Failing Fontan Procedure.

Authors:  Robert W Elder; Fred M Wu
Journal:  Curr Cardiol Rep       Date:  2016-05       Impact factor: 2.931

Review 10.  Central role of the gut epithelial barrier in the pathogenesis of chronic intestinal inflammation: lessons learned from animal models and human genetics.

Authors:  Luca Pastorelli; Carlo De Salvo; Joseph R Mercado; Maurizio Vecchi; Theresa T Pizarro
Journal:  Front Immunol       Date:  2013-09-17       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.